First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
Elizabeth J. Davis(Vanderbilt University Medical Center), Janice M. Mehnert(Rutgers Cancer Institute of New Jersey), Dana B. Cardin(Vanderbilt University Medical Center), Jason A. Clark(Incyte (United States)), Prashanth Hari Dass(Churchill Hospital), Angela Orcurto(University of Lausanne), Juan Martín-Liberal(Royal Marsden NHS Foundation Trust), Rowan Miller(University College Hospital), Sarah P. Blagden(Queen's University Belfast), Thomas Condamine(The Wistar Institute), Dominik Berthold(University Hospital of Lausanne), Daniel C. Cho(NYU Langone Health), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Kristen Spencer(Rutgers Cancer Institute), Xuejun Chen(Incyte (United States)), Jennifer Pulini(Incyte (United States)), John E. Janik(Incyte (United States)), María Vieito(Vall d'Hebron Hospital Universitari)
Cited by 93
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
|JAMA Oncology|2015|656
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
|Annual Review of Medicine|2014|505